X
Pfizer expands venture arm with $600m cash boost
https://pharmaphorum.com/news/pfizer-expands-venture-arm-cash-boost/
Pfizer
NICE recommends Pfizer’s Xalkori in rare lung cancer
NICE has issued a Final Appraisal Determination that recommends the use of Pfizer’s Xalkori (crizotinib) in England under the Cancer Drugs Fund (CDF) for patients with ROS1-positive advanced non-small cell lung cancer (NSCLC).
FDA approves oral treatment for ulcerative colitis
Pfizer’s janus kinase (JAK) inhibitor drug Xeljanz (tofacitinib) has received expanded approval from the FDA for adults with moderately-to-severely-active ulcerative colitis.
Pfizer will have to cut price of AML drug Mylotarg after NICE ruling
NICE blocks access to 65% of patients on cost grounds
FDA approves Pfizer’s epoetin biosimilar Retacrit
Epoetin alfa biosimilars available in EU for more than a decade
Pfizer’s Read resists merger pressure
CEO says investment will focus on pipeline
